

1 **Drug-target Mendelian randomization analysis supports lowering plasma**
2 **ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing**
3 **cardiovascular disease risk**

4 Fredrik Landfors^{1, 2, *}, Peter Henneman³, Elin Chorell¹, Stefan K. Nilsson^{2, 4}, Sander Kersten^{5, 6}

5 ¹ Department of Public Health and Clinical Medicine, Section of Medicine, Umea University, S-901
6 87 Umea, Sweden.

7 ² Lipigon Pharmaceuticals AB, S-907 36 Umea, Sweden.

8 ³ Department of Human Genetics, Amsterdam University Medical Center, Meibergdreef 9, 1105 AZ,
9 Amsterdam, The Netherlands.

10 ⁴ Department of Medical Biosciences, Umea University, S-901 87 Umea, Sweden.

11 ⁵ Nutrition, Metabolism, and Genomics group, Division of Human Nutrition and Health, Wageningen
12 University, 6708WE, Wageningen, the Netherlands.

13 ⁶ Division of Nutritional Sciences, Cornell University, Ithaca, NY 14853, USA.

14 * To whom correspondence should be addressed.

15 **Contact information for the corresponding author:** Fredrik Landfors, Department of Public Health
16 and Clinical Medicine, Umea University, S-901 87 Umea, Sweden; Email:

17 Fredrik.Landfors@umu.se; Phone: +46 (0) 70-454 92 08.

18 **ABSTRACT**

19 *Background and Aims:* APOC3, ANGPTL3, and ANGPTL4 are circulating proteins that are actively
20 pursued as pharmacological targets to treat dyslipidemia and reduce the risk of atherosclerotic
21 cardiovascular disease. Here, we used human genetic data to compare the predicted therapeutic and
22 adverse effects of APOC3, ANGPTL3, and ANGPTL4 inactivation.

23 *Methods:* We conducted drug-target Mendelian randomization analyses using variants in proximity to
24 the genes associated with circulating protein levels to compare APOC3, ANGPTL3, and ANGPTL4 as
25 drug targets. We obtained exposure and outcome data from large-scale genome-wide association studies
26 and used generalized least squares to correct for linkage disequilibrium-related correlation. We
27 evaluated five primary cardiometabolic endpoints and screened for potential side effects across 694
28 disease-related endpoints, 43 clinical laboratory tests, and 11 internal organ MRI measurements.

29 *Results:* Genetically lowering circulating ANGPTL4 levels reduced the odds of coronary artery disease
30 (CAD) (odds ratio, 0.57 per s.d. protein [95%CI,0.47–0.70]) and type 2 diabetes (T2D) (odds ratio, 0.73
31 per s.d. protein [95%CI,0.57–0.94]). Genetically lowering circulating APOC3 levels also reduced the
32 odds of CAD (odds ratio, 0.90 per s.d. protein [95%CI,0.82–0.99]). Genetically lowered ANGPTL3
33 levels via common variants were not associated with CAD. However, meta-analysis of deleterious
34 variants revealed that *ANGPTL3* inactivation protected against CAD (odds ratio, 0.79 per allele [95%CI,
35 0.69–0.90]). Analysis of lowered ANGPTL3, ANGPTL4, and APOC3 levels did not identify important
36 safety concerns.

37 *Conclusion:* Human genetic evidence suggests that therapies aimed at reducing circulating levels of
38 ANGPTL3, ANGPTL4, and APOC3 reduce the risk of CAD. ANGPTL4 lowering may also reduce the
39 risk of T2D.


40 **STRUCTURED GRAPHICAL ABSTRACT**

41 *Key Question:* Does human genetics support that triglyceride-lowering drugs targeting ANGPTL3, ANGPTL4, and APOC3 will reduce the risk of cardiometabolic disease without causing side effects?

42 *Key Finding:* Genetically lowered circulating ANGPTL4 reduced coronary artery disease and type 2 diabetes risk. Genetically lowered ANGPTL3 and APOC3 also reduced coronary artery disease risk, but no impact on type 2 diabetes risk was observed.

43 *Take-home Message:* Human genetics suggest that ANGPTL3, ANGPTL4, and APOC3-lowering medications may prevent CAD. Medicines targeting ANGPTL4 may have added benefits for patients with type 2 diabetes.

GRAPHICAL ABSTRACT



49 **Graphical abstract summarizing the study's methods and findings.**

50 Graphical abstract summarizing the overall study design. The 'Key Findings' figure provides a summary of the results

51 categorized into three groups. The term 'improves' denotes a statistically significant association with a clinically relevant effect

52 magnitude. The term 'weak' refers to a statistically significant association with no clinically significant effect. 'ASCVD' denotes

53 atherosclerotic cardiovascular disease. 'T2D' denotes type 2 diabetes.

54

55 INTRODUCTION

56 APOC3, ANGPTL3, and ANGPTL4 are circulating proteins that regulate plasma cholesterol and
57 triglyceride (TG) levels. They mainly act by inhibiting the enzyme lipoprotein lipase. All three proteins
58 are actively pursued as pharmacological targets to treat dyslipidemia and reduce the risk of
59 atherosclerotic cardiovascular disease. The inactivation of APOC3 using ASOs (Volanesorsen,
60 Olezarsen) has been shown to substantially reduce plasma TG levels in different patient groups with
61 severe hypertriglyceridemia (1). Volanesorsen is a second-generation ASO that was approved in Europe
62 for treating familial chylomicronemia syndrome. Olezarsen is a third-generation ASO that very recently
63 received fast-track designation from the FDA. Currently, several human trials are ongoing with an RNAi
64 against APOC3 called ARO-APOC3.

65 Similar to APOC3, the inactivation of ANGPTL3 using monoclonal antibodies (Evinacumab) (2-6),
66 antisense oligonucleotides (ASOs) (Vupanorsen) (7, 8), and RNAi (ARO-ANG3) has been shown to
67 significantly lower plasma LDL-C and TG levels in various dyslipidemic patients groups (9).
68 Evinacumab was approved in 2021 as a treatment for homozygous familial hypercholesterolemia
69 (HoFH), while Vupanorsen was discontinued in 2021 due to the limited reduction in non-HDL-C and
70 TG and increases in liver fat and enzymes (10). Recent case reports suggest that Evinacumab may
71 promote the regression of atherosclerotic plaques in HoFH patients (11, 12).

72 Whereas the clinical development of anti-APOC3 and -ANGPTL3 treatments have progressed well,
73 therapies targeting ANGPTL4 have faced delay because mice deficient in ANGPTL4 develop lethal
74 mesenteric lymphadenopathy and chylous ascites when fed a diet high in saturated fatty acids (13-15).
75 Whether whole-body inactivation of ANGPTL4 might trigger similar pathological features in humans
76 is unclear. As an alternative pharmacological strategy, inactivating ANGPTL4 specifically in the liver
77 holds considerable promise (16). Despite these challenges, targeting ANGPTL4 presents a promising
78 opportunity, as it may not only lower triglycerides and remnant cholesterol but also redirect lipids away
79 from ectopic sites and towards adipose tissue, potentially protecting against type 2 diabetes (17).

80 Human genetic data can be leveraged to predict the clinical effect of the pharmacological inactivation
81 of genes or proteins. Here, we aimed to compare the predicted therapeutic effects of APOC3,
82 ANGPTL3, and ANGPTL4 inactivation by investigating the biological and clinical impact of
83 inactivation variants in the respective genes. In addition, to address safety concerns, we compared the
84 predicted detrimental effects of APOC3, ANGPTL3, and ANGPTL4 inactivation on relevant disease
85 outcomes. We conclude that therapies specifically aimed at decreasing plasma ANGPTL3, ANGPTL4,
86 and APOC3 levels are expected to reduce the risk of coronary artery disease without raising safety
87 concerns. Therapies targeting ANGPTL4 levels are expected to favorably impact the risk of type 2
88 diabetes. This suggests that reducing ANGPTL4 could offer therapeutic advantages to a wider group of
89 patients with dyslipidemia and type 2 diabetes.

90 **METHODS**

91 **Study design**

92 The study was performed in four sequential steps as summarized in **Figure 1**. First, a two-sample
93 Mendelian randomization (MR) study was conducted to measure the association between *ANGPTL3*,
94 *ANGPTL4*, and *APOC3* lowering with cardiometabolic diseases and risk factors. Second, two-sample
95 MR was conducted to measure the target proteins' association with phenotypes related to potential
96 adverse effects. Third, validation analyses were conducted to further assess the plausibility of the
97 findings obtained from steps 1-2. Lastly, to measure the association between profound genetic
98 inactivation of the target proteins and CAD, deleterious variant analyses in the UK Biobank were
99 performed and meta-analysed with previous studies.

100 **Steps 1-2**

101 **Genetic instruments**

102 To estimate the causal effects of pharmacologically inactivating the *ANGPTL3*, *ANGPTL4*, and
103 *APOC3* genes, we performed two-sample drug-target MR. We used, as instrumental variables (IV),
104 genetic variants within 2.5 kilobase pairs (Kb) of the target gene that had genome-wide significant
105 associations ($P\text{-value} \leq 5 \times 10^{-8}$) with protein abundance (called *cis* protein quantitative trait loci, *cis*-
106 pQTLs) or plasma TG, as determined by genome-wide association studies (GWAS). Variants
107 adjacent to the target genes were clumped at an LD threshold of $r^2 \geq 0.10$ to avoid GLS-related
108 multicollinearity issues. Residual LD was accounted for using the generalized least squares (GLS)
109 IVW estimator described below.

110

111 **Drug-target MR**

112 The precision of the inverse-variance weighted (IVW) estimator can be influenced by LD-related
113 correlation between the genetic IV in the drug target genes *cis*' position. Therefore, we used a GLS IVW
114 MR estimator to correct for this potential source of bias (18, 19). The GLS-corrected MR approach can
115 be conceptualized as combining the independent information of variants near a target gene while
116 maintaining robust standard errors through weighting for their LD-related correlation. Further
117 information regarding Drug-target MR methodology, GLS, LD matrix sensitivity, and sample overlap
118 bias are found in the **Supplemental Methods**.

119 Due to the complex structure of the *APOA1-APOA5-APOC3* locus, we supplemented the original
120 analyses with a second model of *APOC3* lowering. In this model, *APOC3* lowering was instrumented
121 through the *APOC3 c.55+IG>A* splice donor loss variant solely, as this variant is a high-confidence
122 predicted loss-of-function variant (gnomAD Genome Aggregation Database v.4.0.0,
123 <https://gnomad.broadinstitute.org>) independent of other common variants in this genomic region (20).
124 The *APOC3 c.55+IG>A* MRs used a Wald ratio estimator. Furthermore, we used *LPL*-adjacent and
125 genome-wide TG-associated variants as positive controls. *LPL* was analyzed using drug-target MR. For

126 the genome-wide TG-associated variant MR, we tested the causal effect of TG using variants in
127 chromosomes 1-22 associated with TG at P-value $\leq 5 \times 10^{-8}$. An LD clumping window of 500 Kb and a
128 threshold of $r^2 \geq 0.001$ was applied before analysis using an IVW estimator.

129 **Data sources**

130 Plasma protein abundance was measured in GWAS using the SomaScan and Olink platforms (21, 22).
131 GWAS data on plasma TG, LDL cholesterol, HDL cholesterol, apolipoprotein B, apolipoprotein A1,
132 and lipoprotein(a) were retrieved from the 2018 Neale Lab UK biobank analysis
133 (<http://www.nealelab.is/uk-biobank/>). For the functional variant analyses, genetic association data on
134 TG, LDL cholesterol, and HDL cholesterol were retrieved from the AstraZeneca UK biobank exome
135 sequencing-based phenome-wide association study (PheWAS) portal (23). We obtained outcome
136 summary data from GWAS of six cardiometabolic disease endpoints, 16 cardiometabolic risk markers,
137 43 routine clinical chemistry tests, 11 internal organ MRI measurements, and five abdominal
138 lymphadenopathy-related phenotypes (see **Table 1**, **Supplemental Table 1**, and **Supplemental**
139 **Methods**). Phenome-wide MR analyses were conducted in FinnGen and the UK biobank. FinnGen
140 integrates genotype data from Finnish biobanks with longitudinal health registry data (24). The UK
141 Biobank is a large-scale research resource containing genetic, blood chemistry, imaging, and health
142 record data from half a million UK participants (25). The FinnGen data freeze 10 and UK biobank meta-
143 analysis (<https://public-metareresults-fg-ukbb.finnngen.fi>) stores genetic association statistics on 694
144 disease-related outcomes from 301,552–882,347 individuals. Further details on the selection of GWAS
145 and the definition of exposures and outcomes are given in the **Supplemental Methods**.

146 **Colocalization analyses**


147 Drug-target MR substantially relies on the assumption that LD (a phenomenon in which neighboring
148 genetic variants are inherited together more frequently than anticipated by chance (26)) does not
149 confound the association between variant and outcome. In cases where there are distinct genetic variants
150 affecting both the exposure and the outcome, and they are connected through LD, there is a risk of
151 making incorrect conclusions (27). To limit this issue, we performed colocalization analyses, which test
152 whether two independent association signals in the same gene region are consistent with having a single
153 shared causal variant (that is, testing if the association signals are ‘colocalized’) (28). To assess possible
154 confounding from LD, all drug target MR analyses were complemented by colocalization analysis of
155 the 500 Kb (± 250 Kb) region surrounding each target gene (28). Further details regarding the
156 colocalization analyses are provided in the **Supplemental Methods**.

157

158 **Lymphadenopathy and phenome-wide MR analyses**

159 A Wald ratio estimator was used for the single-variant MR of lymphadenopathy-related phenotypes and
160 the phenome-wide MR conducted in FinnGen (29). The variants were selected based on being within

161 2.5 Kb of the drug target gene, their strength of association with target protein plasma abundance ($P \leq$
162 5×10^{-8}), their strength of association with triglyceride levels ($P \leq 5 \times 10^{-8}$), availability, and their
163 functional consequence. For further details regarding genetic instrument justification for the phenome-
164 wide MRs, see the **Supplemental Methods**.



165
166
167
168
169

Figure 1. Study design flow chart summarizing the objective, methods, and results.

'LD' indicates linkage disequilibrium. 'n.s.' denotes not significant. 'LPL' indicates lipoprotein lipase. 'MR' indicates Mendelian Randomization. 'EL' indicates endothelial lipase. 'CAD' indicates coronary artery disease. 'IVW' indicates inverse-variance weighted.

170

Table 1. Description of GWAS data sets

| | No | Trait | First author (year) | Consortium | Sample size (events/total) | Population |
|-----------------------|----|---|-------------------------------------|--|---|------------------------|
| pQTL | 1 | Plasma protein abundance (SomaScan) | Ferkingstad (2021) (21) | deCODE | 35,559 | Icelandic |
| | 2 | Plasma protein abundance (Olink) | Dhindsa (2023) (22) | Not available | 50,829 | British |
| Diseases | 3 | Coronary artery disease | Aragam (2022) (30) | CARDioGRAMplusC4D; EPIC-CVD | 181,522 / 1,165,690 | European |
| | 4 | Chronic kidney disease | Wuttke (2019) (31) | CKDGen | 41,395 / 480,698 | European |
| | 5 | Ischemic stroke | Mishra (2022) (32) | GIGASTROKE | 62,100 / 1,296,908 | European |
| | 6 | Non-alcoholic fatty liver disease | Ghodsian (2021) (33) | Not available | 8,434 / 787,048 | European |
| | 7 | Type 2 diabetes | Mahajan (2018) (34) | DIAGRAM | 74,124 / 898,130 | European |
| Risk factors | 8 | Plasma total, HDL, and LDL cholesterol; Apolipoprotein B; Apolipoprotein A1; TG; Lipoprotein(a); HbA1c | Neale lab (2018) | Not available | 273,896 – 344,278; | British |
| | 9 | HDL, and LDL cholesterol; TG; NMR metabolomics | Wang (2021) (23); Nag (2023) (35) | AZPheWAS | 95,077 – 376,311 | British |
| | 10 | NMR metabolomics, including total lipoprotein phospholipids | Elsworth (2020) (36) | MRC-IEU | 110,058 – 115,078 | British |
| | 11 | Systolic blood pressure; diastolic blood pressure | Evangelou (2018) (37) | Not available | 757,601 | European |
| | 12 | Body mass index; waist-hip ratio | Pulit (2018) (38) | GIANT | 694,649 – 806,834 | European |
| | 13 | Body fat percentage; NMR total triglycerides; NMR total phospholipids | Elsworth (2020) (36) | MRC-IEU | 115,078 – 454,633 | British |
| | 14 | Plasma creatinine estimated glomerular filtration rate (eGFR); cystatin C eGFR | Stanzick (2021) (39) | CKDGen | 1,004,040; 1,201,909 | European; 86% European |
| Safety-related | 15 | Magnetic resonance imaging of internal organs | Liu (2021) (40) | Not available | 25,617 – 32,860 | British |
| | 16 | Routine blood chemistry tests | Neale lab (2018) | Not available | 30,565 – 350,812 | British |
| | 17 | Acute lymphadenitis; Acute peritonitis; Ascites; Intestinal malabsorption; Non-infectious lymphatic disorders | Neale lab (2018); Kurki (2023) (24) | Not available; FinnGen | 620 – 4,982 / 270,172 – 382,633; 798 – 1643 / 295,812 – 341,350 | British; Finnish |
| | 18 | Phenome-wide association study | FinnGen (2023) (24) | Pan-UK Biobank + FinnGen meta-analysis | 110 – 279,543 / 301,552 – 882,347 | British; Finnish |

[7] 'NMR' indicates nuclear magnetic resonance spectroscopy.

172 **Step 3**

173 **Genetic mimicry analyses**

174 Genetic mimicry analysis was used to compare the metabolic concordance between common and
175 deleterious variants adjacent to the *ANGPTL3*, *ANGPTL4*, and *APOC3* genes. This method uses linear
176 regression to determine the extent of similarity between different variants' genetic associations in high-
177 dimensional data sets (41, 42). The degree of concordance was reported as the coefficient of
178 determination (R^2). Genetic associations between the common variants and 167 plasma metabolites were
179 measured by drug-target MR with plasma TGs as the exposure using data sets 8 and 10 (see **Table 1**).
180 Deleterious variants were defined as any protein-truncating variant with an allele frequency <0.05 or
181 missense variants with a REVEL pathogenicity prediction score >0.25 and allele frequency <0.00025
182 (see **Supplemental methods**). The effects of deleterious variants were determined by regressing plasma
183 concentration of metabolites on deleterious variant carrier status in 181,672 UK Biobank participants
184 (see **Supplemental Methods** for details).

185

186 **Robustness checks and sensitivity analyses**

187 We performed sensitivity MR analyses of *ANGPTL3*, *ANGPTL4*, *APOC3*, *LPL*, and *LIPG* on CAD by
188 restricting the genetic instrument selection to variants within these target genes predicted to have
189 functional impacts. This strategy aimed to mitigate potential biases arising from common non-coding
190 small-effect variants outside the target genes, which could be confounded due to linkage disequilibrium
191 with other genes in the same genomic region. Ensembl Variant Effect Predictor (VEP) version 109 (43)
192 was used to annotate variants within 2.5 Kb of the target gene associated ($P \leq 0.01$) with target protein
193 levels and plasma triglycerides. Non-coding variants outside of the 5' untranslated region (UTR), 3'
194 UTR, or splice site regions were filtered out and excluded from further analysis, as were missense
195 variants lacking SIFT deleterious or PolyPhen likely or probably damaging annotations. MR was
196 conducted for single variants using the Wald ratio estimator, and meta-analysis was performed using a
197 random-effects IVW estimator.

198 **Step 4**

199 **Meta-analysis of the impact of deleterious variants on CAD**

200 We conducted genetic association analyses in the UK Biobank (see **Supplemental Methods**) and meta-
201 analyzed the results with previous studies to assess how deleterious variants in *ANGPTL3*, *ANGPTL4*,
202 and *APOC3* impact CAD risk. To minimize the influence of incorrect genotype calls for rare variants,
203 the meta-analysis was limited to studies where genotypes were determined by DNA sequencing. When
204 multiple papers reported on individuals from overlapping cohorts or case-control studies, we selected
205 the substudy with the largest sample size for inclusion in the meta-analysis. The meta-analyses were
206 restricted to European ancestries. We determined the impact of the inactivating variants on CAD risk
207 per mmol/L reduction of TG and per inactivating allele using fixed-effect IVW estimators. If no within-

208 sample association of inactivating variants with TG concentrations (in mmol/L) was available, the
209 combined IVW meta-analysis TG estimate was used as the denominator to determine the CAD odds per
210 mmol/L TG effect. Statistical heterogeneity across studies was estimated by calculating the Cochran Q
211 statistic.

212

213 **Statistics**

214 **Multiple testing**

215 P-values and 95% confidence intervals (CI) are reported using analysis-type Bonferroni multiple
216 comparisons correction. In the primary MR analyses, we corrected for the five cardiometabolic disease
217 outcomes that were run across three different drug-target gene exposures (*ANGPTL3*, *ANGPTL4*,
218 *APOC3*) for protein abundance, and four genes for the TG exposure (*ANGPTL3*, *ANGPTL4*, *APOC3*,
219 *LPL*). Additionally, we included five genome-wide triglyceride MR models, totaling 40 comparisons
220 for the cardiometabolic disease outcomes. In the cardiometabolic risk factor MR analyses of *cis*-pQTLs,
221 we made corrections for 45 multiple comparisons (15×3). Similarly, imaging and blood chemistry MR
222 analyses were corrected for 33 (11×3), and 129 (43×3) multiple comparisons, respectively. We did not
223 perform multiple comparison corrections for the *ANGPTL4*-targeted MR analyses of the
224 lymphadenopathy-related phenotypes. This was because identifying potential safety concerns that
225 needed to be addressed was considered more critical than stringent multiplicity correction for these
226 specific outcomes. Similarly, the primary motivation for performing the functional variant-limited CAD
227 MR analyses and deleterious variant meta-analysis was to reduce the risk of false-negative findings.
228 Additionally, we wanted to ensure that these CIs and P-values remained comparable across different
229 studies. These CIs and P-values were, therefore, not corrected for multiple comparisons. The
230 significance threshold in the phenome-wide *cis*-pQTL MR analyses was set at 2082 multiple
231 comparisons (694 phenotypes in the FinnGen R10 and UK biobank meta-analysis, times three genes).

232 **RESULTS**

233 The results of the drug-target MR analyses of cardiometabolic diseases, cardiometabolic risk factors,
234 and the safety-related endpoints are presented in **Figure 2**, **Figure 3**, and **Figure 4**, respectively. MR
235 scatter, colocalization plots, and results tables with greater detail are provided in **Supplemental Figures**
236 **1-2** and **Supplemental Table 2**. Detailed PheWAS results are provided in **Supplemental Tables 6-9**.
237 The genetic variants selected for inclusion as instrumental variables in one or more of the MR analyses
238 are shown in **Table 2**.

Table 2. Genetic instruments

| | rsID | Variant | HGVS | Consequence | Frequency | Effect (P-value) | | | |
|----------------|--------------------------|------------------|-------------------------|-------------------------------|-----------|---------------------------------|---------------------|---------------------------------|---------------------------------|
| | | | | | | Protein (SomaScan) | Protein (Olink) | Protein (ELISA) [‡] | TG |
| ANGPTL3 | rs79151558 | 1:62595131:A>G | | Upstream variant | 0.028 | -0.32 (8.1e-39) | -0.27 (1.4e-36) | - | -0.06 (5.4e-13) |
| | rs11207997* | 1:62596235:C>T | | Upstream variant | 0.338 | -0.22 (1.2e-144)* | -0.31 (<2e-308)* | - | -0.08 (2.7e-221)* |
| | rs17123728 | 1:62602628:G>A | c.931+248G>A | Intron variant | 0.04 | n.s. | - | - | 0.03 (2.5e-08) |
| | rs35285100 | 1:62603486:T>C | c.932-483T>C | Intron variant | 0.071 | 0.10 (2.3e-09) | 0.08 (6.3e-10) | - | n.s. |
| | rs10789117* | 1:62606594:A>C | | Downstream variant | 0.354 | -0.22 (1.7e-144)* | -0.31 (<2e-308)* | - | -0.08 (1.6e-221)* |
| | rs6678483* | 1:62608771:C>A | | Downstream variant | 0.354 | -0.22 (1.7e-144)* | -0.31 (<2e-308)* | - | -0.08 (2e-221)* |
| ANGPTL4 | rs116843064 [‡] | 19:8364439:G>A | p.Glu40Lys [‡] | Missense variant [‡] | 0.024 | -0.32 (6.6e-35) | -0.35 (6.8e-48) | -0.45 (4.8e-05) [‡] | -0.21 (3.2e-127) |
| | rs149480839 | 19:8368237:C>T | c.548-982C>T | Intron variant | 0.03 | n.s. | - | - | -0.05 (2.6e-14) |
| | rs139469000 | 19:8376253:C>T | | Downstream variant | 0.28 | n.s. | - | - | -0.02 (1.7e-09) |
| APOC3 | rs2727788 | 11:116828247:C>A | | Upstream variant | 0.262 | n.s. | - | - | -0.05 (7.3e-83) |
| | rs138326449 | 11:116830638:G>A | c.55+1G>A | Splice donor variant | 0.002 | -2.19 (3.2e-142) | - | - | -0.86 (3.4e-157) |
| | rs5141 [†] | 11:116831407:T>C | c.179+511T>C | Intron variant | 0.916 | -0.17 (2.1e-38) [†] | - | - | -0.19 (<2e-308) [†] |
| | rs5132 | 11:116832062:C>T | c.180-702C>A | Intron variant | 0.015 | n.s. | - | - | 0.06 (3.1e-08) |
| | rs12721031 | 11:116833789:C>T | | Downstream variant | 0.023 | n.s. | - | - | -0.06 (2.6e-12) |
| | rs10750098 [†] | 11:116834852:G>T | | Downstream variant | 0.115 | -0.17 (2.1e-38) [†] | - | - | -0.19 (<2e-308) [†] |
| | rs12721028 | 11:116834874:A>G | | Downstream variant | 0.159 | n.s. | - | - | 0.04 (2e-35) |
| | rs12718462 | 11:116835003:T>C | | Downstream variant | 0.066 | n.s. | - | - | -0.05 (1.8e-22) |

239 Showing the genetic variants selected for inclusion as instrumental variables in one or more of the MR analyses whose results
 240 are shown in **Figures 2-4**. The specific instruments used in each separate MR analysis are provided in **Supplemental Table 2**.
 241 *Cis*-pQTLs meeting the significance threshold (P-value $\leq 5 \times 10^{-8}$) were initially identified in the SomaScan protein GWAS. These
 242 *cis*-pQTLs were then cross-referenced with the UK Biobank Olink protein GWAS to determine if the effect estimates were
 243 consistent. Variant consequences were retrieved from the Ensembl Variant Effect Predictor (version 109) (43). 'Effect' indicates
 244 the 1 s.d. protein abundance (retrieved from (21, 22)) or mmol/L TG change (retrieved from <http://www.nealelab.is/uk-biobank/>)
 245 per allele. 'rsID' denotes Reference single nucleotide polymorphism ID. 'HGVS' indicates Human Genome Structural Variation
 246 Consortium nomenclature for sequence variants. 'n.s.' indicates not significant.

247 *† These variants were in strong linkage disequilibrium (LD) and, therefore, showed the same associations with TG levels and
 248 plasma ANGPTL3/APOC3 abundance. Because they were in strong LD, they were never included in the same MR model (see
 249 **Methods** and **Supplemental Table 2**).

250 ‡ The association between *ANGPTL4* p.E40K coding variant carrier status and plasma *ANGPTL4* protein was confirmed in a
 251 separate study by ELISA using antibodies that were shown by Western blotting to similarly detect wildtype *ANGPTL4* and
 252 *ANGPTL4* containing the E40K substitution, indicating that the association was not attributable to epitope-binding artifacts (see
 253 **Supplemental Methods**).

254 **Step 1**

255 **Drug-target MR of cardiometabolic diseases**

256 Genetically mediated changes in plasma ANGPTL3 protein abundance were not associated with a
257 reduced risk of any cardiometabolic outcome (**Figure 2A**), nor were *ANGPTL3*-mediated changes in
258 plasma TG (**Figure 2B**).

259 The p.E40K coding variant was the only variant that qualified as a *cis*-pQTL in the *ANGPTL4* region.
260 *ANGPTL4* p.E40K is a common missense variant (allele freq. ~2% in Europeans) that destabilizes
261 ANGPTL4 after secretion and prevents ANGPTL4 from inhibiting LPL (44). The association between
262 the *ANGPTL4* p.E40K coding variant and plasma ANGPTL4 protein was validated via ELISA in a
263 separate cohort. The association was -0.45 s.d. protein per allele, $P=4.8\times 10^{-5}$, comparable to the
264 associations detected with the Olink and Somascan platforms (see **Table 2**). The ELISA antibodies
265 detected wild-type and E40K ANGPTL4 proteins to a comparable degree, as determined by Western
266 blot analysis (see **Supplemental Methods** for details). This suggests that the observed association was
267 not attributable to epitope-binding artifacts.

268 Changes in ANGPTL4 protein levels via *ANGPTL4* p.E40K were associated with a decreased risk of
269 CAD (OR: 0.57, $P=1\times 10^{-19}$), and T2D (OR: 0.73, $P=0.001$) (**Figure 2A**). Similarly, changes in plasma
270 TG levels via three *ANGPTL4*-adjacent variants were associated with a decreased risk of CAD (OR:
271 0.43, $P=1\times 10^{-21}$), and T2D (OR: 0.62, $P=4\times 10^{-4}$) (**Figure 2B**). In addition, colocalization analyses
272 indicated a high probability of *ANGPTL4* p.E40K being a shared causal variant for ANGPTL4 levels
273 and TG levels with CAD and T2D (pp.H₄: 98–100%) (**Figures 2A-B**).


274 Changes in APOC3 levels caused by *APOC3*-adjacent variants were associated with a reduced risk of
275 CAD (OR: 0.90, $P=0.009$) (**Figure 2A**), as were changes in TG levels through *APOC3*-adjacent variants
276 (OR: 0.80, $P=4\times 10^{-11}$). The *APOC3* c.55+1G>A splice donor loss variant had a substantial impact on
277 plasma APOC3 levels (-2.19 s.d. protein, $P=3.2\times 10^{-142}$) and plasma TG (-0.86 mmol/L, $P=3.4\times 10^{-157}$)
278 (**Table 2**). When compared to the model allowing for multiple variants in the *APOC3* region, APOC3
279 lowering modeled through the *APOC3* c.55+1G>A variant demonstrated a comparable correlation with
280 CAD in terms of the direction of its effect. However, the association was non-significant (**Figure 2**).

281 Similar to APOC3 and ANGPTL4, changes in plasma TG levels through *LPL*-adjacent variants were
282 associated with a reduced risk of CAD (OR: 0.69, $P=1\times 10^{-24}$), NAFLD (OR: 0.66, $P=0.021$), and T2D
283 (OR: 0.73, $P=6\times 10^{-10}$) (**Figure 2B**).

284

Cardiometabolic diseases

A. Exposure: Target protein abundance



B. Exposure: Triglycerides




Figure 2. Results of MR analyses of cardiometabolic disease outcomes.

A: Forest plot and table of the *cis*-pQTL-based MR analyses. 'Events/total' indicates the outcome study's case count and total sample size. 'No. SNPs' specifies the number of variants included in the MR model. Zero SNPs indicate that none of the genetic instruments were detected in the outcome data set. 'Coloc.' shows the colocalization hypothesis ($H_{0.4}$) with the highest posterior probability (see the 'Methods' section for details about their interpretation). **B:** Results of the MR analysis using TG levels as the exposure. The 'Genome-wide TG QTLs' and 'LPL' models were positive controls. 'Genome-wide TG QTLs' indicate the MR model that included independent ($r^2 < 0.001$, 500Kb clumping window) variants associated with TG levels ($P \leq 5 \times 10^{-8}$) across chromosomes 1-22. 'LPL' denotes lipoprotein lipase.


285
286
287
288
289
290
291
292
293

294 **Drug-target *cis*-pQTL MR of cardiometabolic risk factors**

295 Genetically lowered plasma ANGPTL3 levels were associated with reduced total cholesterol (-0.27
296 mmol/L, $P=2\times 10^{-107}$), TG (-0.34 mmol/L, $P=6\times 10^{-206}$), LDL-C (-0.15 mmol/L, $P=2\times 10^{-57}$), ApoB (-0.03
297 g/L, $P=3\times 10^{-36}$), and ApoA-I levels (-0.05 g/L, $P=1\times 10^{-51}$), while the effect on HDL-C was comparatively
298 weak (-0.02 mmol/L, $P=4\times 10^{-5}$) (**Figure 3**).

299 Genetically lowered plasma ANGPTL4 levels instrumented through the p.E40K variant were associated
300 with reduced plasma TG (-0.65 mmol/L, $P=1\times 10^{-125}$) and weakly reduced ApoB levels (-0.02 g/L,
301 $P=0.038$), as well as increased ApoA1 (0.11 g/L, $P=1\times 10^{-55}$) and HDL-C levels (0.24 mmol/L, $P=7\times 10^{-134}$) (**Figure 3**). Genetically lowered plasma ANGPTL4 levels were also associated with modest
302 reductions in the waist-hip ratio (-0.09 s.d., $P=0.004$), and a small increase in body fat percentage (0.07
303 s.d., $P=0.008$) (**Figure 3**).

305 Genetically lowered plasma APOC3 levels were associated with reduced TG levels (-0.58 mmol/L, $P <$
306 2×10^{-308}) (**Figure 3**). APOC3 levels were also associated with ApoB (-0.03 g/L, $P=1\times 10^{-22}$), LDL-C (-
307 0.10 mmol/L, $P=6\times 10^{-18}$), HDL-C (0.16 mmol/L, $P = 2\times 10^{-238}$), and total cholesterol (-0.08 mmol/L,
308 $P=5\times 10^{-6}$) (**Figure 3**). In terms of association and effect directionality, these results closely resembled
309 those of the *APOC3 c.55+1G>A* model (**Figure 3**).



310
311
312
313
314

Figure 3. Results of MR analyses of cardiometabolic disease risk factors.

The results are presented as bar plots, showing the magnitude of the effect per s.d. lowered protein abundance. The red lines indicate the 95% CI. The results from *cis*-pQTL MR of the estimated glomerular filtration rate (eGFR) by Cystatin C and plasma Creatinine, respectively, are given in **Supplemental Figure 3**.

315 Step 2


316 Drug-target MR of potential adverse effects

317 Genetic lowering of plasma protein levels of the target genes was not associated with any of the MRI
318 imaging endpoints (**Figure 4A**). 9, 3, 9, and 6 out of the 43 routine clinical laboratory tests showed
319 statistically significant associations by drug-target cis-pQTL MR of the *ANGPTL3*, *ANGPTL4*,
320 *APOC3*, and *c.55+1G>A* models, respectively (**Figure 4B**). The effect magnitudes were weak. For
321 example, genetically lowered *ANGPTL3* and *APOC3* levels were significantly associated with
322 increased platelet count. However, the effect was estimated to be $4-5 \times 10^9$ cells/L (equalling 0.06-0.08
323 s.d.) per s.d. lowered plasma protein levels, which was minimal compared to the population mean value
324 of 252×10^9 cells/L.

325 Given that safety concerns have arisen from preclinical models of *ANGPTL4* deficiency, we conducted
326 targeted cis-pQTL MR analyses of *ANGPTL4* on disease phenotypes that may be associated with
327 abdominal lymphadenopathy. The mechanism behind the fatal chylous lymphadenopathy observed in
328 mice was purportedly the loss of inhibition of LPL in macrophages, which caused them to take up excess
329 lipids, leading to massive inflammation in the mesenteric lymph system (14). Exposure to *ANGPTL4*
330 inactivation was instrumented using two different models: by the *ANGPTL4* p.E40K coding variant, and
331 by the *ANGPTL4* p.Cys80frameshift (fs) variant. *ANGPTL4* p.Cys80fs is a high-confidence predicted
332 loss-of-function variant (gnomAD v.4.0.0). It is enriched in Finns compared to non-Finnish Europeans
333 (allele frequency: 0.63% vs. 0.05%). Cis-pQTL MR via the relatively common *ANGPTL4* p.E40K
334 variant was conducted at five different phenotypes that may be related to lymphadenopathy and
335 malabsorptive states. Four had overlapping phenotype codes between the UK biobank and FinnGen and
336 were meta-analyzed using IVW meta-analysis. *ANGPTL4* levels via p.E40K were not associated with
337 any of the five phenotypes (**Figure 4C**). However, since the confidence intervals were wide, we cannot
338 fully exclude an association of p.E40K within this interval. Genetically lowered plasma *ANGPTL4*
339 levels via the *ANGPTL4* p.Cys80fs variant were not associated with any of the four FinnGen phenotypes
340 that may be related to lymphadenopathy and malabsorptive states (**Figure 4C**).

341 To investigate if there was any genetic evidence for unknown *ANGPTL4*-mediated side effects, we
342 performed cis-pQTL MR on 694 disease-related phenotypes in FinnGen and the UK Biobank via the
343 *ANGPTL4* p.E40K and p.Cys80fs variants. Using a phenome-wide significance threshold of $P \leq \frac{0.05}{3 \times 694}$,
344 we found no evidence for increased risk of any endpoint via p.E40K- or p.Cys80fs-lowered *ANGPTL4*
345 levels (**Figure 4D**). Instead, we found phenome-wide evidence that p.E40K reduced the risk of four
346 CAD-related phenotypes, including myocardial infarction and one T2D-related phenotype, while also
347 being associated with a lowered probability of statin prescription, lipoprotein disorders, and
348 hypercholesterolemia (**Figure 4D**). Additionally, *ANGPTL4* p.Cys80fs was associated with a decreased
349 risk of two T2D-related outcomes and a lowered probability of statin prescription and
350 hypercholesterolemia diagnosis (**Figure 4D**).

351 The phenome-wide MR results of lowered plasma ANGPTL4 levels were compared with ANGPTL3
352 and APOC3 by cis-pQTL MR of the 694 FinnGen and UK Biobank endpoints using the *ANGPTL3*
353 *c.*52_*60del* and *APOC3 c.55+1G>A*. Genetically lowered plasma ANGPTL3 levels were associated
354 with a reduced risk of being prescribed statin medication, two lipid-related diagnosis codes but not any
355 other patient-related outcome (**Supplemental Figure 4A**). *APOC3 c.55+1G>A* was associated with a
356 reduced risk of statin prescription but not any other endpoint (**Supplemental Figure 4B**).



357
358
359
360
361
362
363
364

Figure 4. Results of MR analysis of potential adverse effects.

A: *Cis*-pQTL MR results on the imaging outcomes. Bar plots and red lines indicate the effect and 95% CI:s. 'scWAT' indicates subcutaneous white adipose tissue. 'vol.' indicates volume. **B:** *Cis*-pQTL MR of the clinical laboratory outcomes. The red bars indicate the 95% CI. The black dots indicate the effect point estimate. * indicate $P < 0.05$. ** indicates $P < 0.05$ with a shared causal variant (H_4). A list explaining the abbreviations is provided in the supplemental material (**Table S1**). **Supplemental Figure 5** shows the results on a 1-s.d. scale. **C:** Results of ANGPTL4 *cis*-pQTL MR of mesenteric lymphadenopathy and malabsorption-related phenotypes. **D:** Volcano plot displaying the results of ANGPTL4 *cis*-pQTL phenome-wide MR scans on

365 694 outcomes in the FinnGen and UK Biobank meta-analysis (see **Table 2** and **Supplemental Table 1** for the reference and
366 link to data, respectively). The y-axis solid straight lines indicate the phenome-wide significance threshold.

367 **Step 3**

368 **Common variants in *ANGPTL3*, *ANGPTL4*, and *APOC3* share their metabolic fingerprint with**
369 **deleterious variants**


370 In line with a previous investigation (45), we found no significant association between *ANGPTL3*
371 inactivation via common variants and CAD. Previously, however, evidence was presented that
372 deleterious variants in *ANGPTL3* are associated with a decreased risk of CAD (46, 47). As the common
373 variants adjacent to *ANGPTL3* only modestly impacted plasma lipids, it could be argued that they do
374 not accurately reflect the effects of more profound *ANGPTL3* inactivation. Therefore, we examined
375 whether common variants adjacent to *ANGPTL3*, *ANGPTL4*, and *APOC3* mimicked the effects (that is,
376 showed the same effect directionality) of deleterious variants.

377 All common variants adjacent to *ANGPTL3*, *ANGPTL4*, and *APOC3* were highly concordant with
378 deleterious variants within the same gene (**Figure 5A-C**). One hundred sixty-seven metabolite
379 associations near *ANGPTL3* showed a high concordance metric (R^2) of 84% between the common
380 variants and deleterious models. *ANGPTL4* common variants were also highly concordant with
381 *ANGPTL4* deleterious variants, having an R^2 of 86%. *APOC3* showed a concordance metric R^2 of 87%.
382 These results demonstrate that the common genetic variations adjacent to *ANGPTL3*, *ANGPTL4*, and
383 *APOC3* would be valid genetic instruments reflecting a modest “knock-down” of each respective gene.
384

385 **Comparative drug-target MR of LPL and endothelial lipase (EL) reveals that in order to achieve**
386 **CAD benefits, *ANGPTL3* inhibition should primarily target LPL rather than EL**

387 *ANGPTL3* targets both EL and LPL and may thus influence CAD via two independent pathways (48).
388 To compare the effects of these two target enzymes, we analyzed the effects of genetically instrumented
389 EL and LPL activity on CAD by performing functional-variant limited MR of the *LIPG* (encoding EL)
390 and *LPL* genes. We used the preferred enzyme substrate as the exposure, as EL prefers lipoprotein
391 phospholipids, whereas LPL primarily hydrolyzes lipoprotein TGs (49). We detected two functional
392 *LPL* variants and four functional *LIPG* variants with small to large effects on plasma TG/lipoprotein
393 phospholipids (range: 0.02 – 0.6 s.d. per allele).

394 MR analysis of *LPL* and *LIPG* found opposing significant associations with CAD for LPL (IVW meta-
395 analysis: OR: 0.74, $P=1\times 10^{-4}$) and EL (IVW meta-analysis OR: 1.38, $P=5\times 10^{-7}$) (**Figure 5D**). These
396 findings suggest that increased activity of LPL protects against the development of atherosclerosis,
397 whereas heightened activity of EL may contribute to the acceleration of atherosclerosis. The contrasting
398 impact of genetic EL and LPL activity on CAD risk suggests that for *ANGPTL3* inactivation to lower
399 CAD risk, it may need to have a greater impact on LPL activity compared to EL activity.



400
 401 **Figure 5. Results of validation analyses.**
 402 The concordance between the effect directionality of CVs and PTVs is displayed using scatter plots with a regression line. **A:**
 403 Comparison of the effect directionality between *ANGPTL3* CVs and PTVs. **B:** *ANGPTL4* CVs vs. PTVs. **C:** *APOC3* CVs vs.
 404 PTVs. 'R²' represents the coefficient of determination. 'Int.' indicates the regression line intercept. The color of the scattered dots
 405 indicates the lipid class of the NMR parameter. The collapsing model estimates were scaled by their 1-s.d. effect on plasma TGs
 406 to improve interpretability. **D:** Forest plots and tables showing the results of the CAD MR analysis focusing on functional
 407 variants in *LPL* and *LIPG*. Genetic association summary statistics of *LIPG* with the exposure were extracted from the UK
 408 biobank NMR study of 115,078 individuals retrieved from (36). *LPL* variant associations were retrieved from the same data set.

409 CAD data was from the Aragam et al. meta-analysis (30). **E:** Forest plots and tables showing the results of the CAD MR
410 analysis that limited the selection of genetic instruments to functional variants in *ANGPTL3* and *ANGPTL4*. "Freq." represents
411 the alternative allele frequency. "info" represents the imputation quality metric derived from the outcome GWAS. Variant effects
412 on plasma lipids were retrieved from (23). The *ANGPTL4* p.Glu40Lys (p.E40K) estimates differ slightly from *Figure 2* because a
413 slightly different estimator and UK Biobank subcohort were used to measure the association between the functional variants and
414 plasma TGs.

415 **Step 4**


416 **Deleterious variants in *ANGPTL3*, *ANGPTL4*, and *APOC3*, and the risk of CAD**

417 Two previous studies found that deleterious variants in *ANGPTL3* protected against CAD (3, 46). In an
418 effort to reproduce these findings, we performed a sensitivity MR analysis of CAD and limited the
419 selection of genetic instruments to functional variants. Functional annotations were detected for four
420 *ANGPTL3*, two *ANGPTL4*, and one *APOC3* variant. The detected *APOC3* variant was the *c.55+IG>A*
421 splice donor loss variant, which was already reported in **Figures 2-4**. The other variants associated with
422 lowered protein levels and triglycerides, with effect sizes ranging from profound to modest (protein
423 range: -2.53– -0.28; TG range -0.28– -0.62) (**Figure 5E**) (22). The variants were analyzed individually
424 and together using random-effects IVW meta-analysis. *Cis*-pQTL MR of the *ANGPTL3* variants
425 indicated that *ANGPTL3* protein levels were not significantly associated with CAD, individually or
426 together (meta-analysis IVW OR per s.d. TG: 0.94, P=0.34) (**Figure 5E**). By contrast, reduced
427 *ANGPTL4* protein levels were associated with a decreased risk of CAD (meta-analysis IVW OR: 0.45
428 per s.d. TG, P=2×10⁻¹⁰) (**Figure 5E**).

429 Considering the beneficial effects of *ANGPTL3*, *ANGPTL4*, and *APOC3* on plasma lipids, it was
430 expected that genetic inactivation of these proteins would confer protection against CAD. However, the
431 *ANGPTL3* MR analyses focusing on common variants and MR of functional variants (identified
432 through DNA microarrays) did not support this hypothesis. Therefore, we pursued a meta-analysis of
433 DNA sequencing-based studies that studied the effect of *ANGPTL3*, *ANGPTL4*, and *APOC3* deleterious
434 variants on CAD. The rationale for excluding DNA microarray and exome bead chip-based studies was
435 the potential risk of introducing measurement error for rare variants (50, 51), leading to bias towards the
436 null hypothesis. DNA-sequencing-based substudies from previous papers (3, 46, 52, 53), were extracted
437 and analyzed together with genetic association analyses conducted in the UK Biobank. Loss-of-function
438 variant genetic association effect sizes typically range from -1 to -3 s.d. for their affected protein (22).
439 The carrier status of deleterious variants was associated with substantial decreases in protein levels for
440 both *ANGPTL3* (-1.29 s.d. protein, P=9×10⁻³²) and *ANGPTL4* (-1.33 s.d. protein, P=1.4×10⁻⁴³). *APOC3*
441 protein levels were not measured in the UK Biobank. However, *APOC3* deleterious variants were
442 associated with a significant reduction in TG (-0.68 mmol/L TG, P=1×10⁻⁸²).

443 The results of the meta-analysis are presented in **Figure 6**. The presence of *ANGPTL3* deleterious
444 variants was associated with reduced CAD risk (meta-analysis IVW OR: 0.41 per TG, P=3×10⁻⁵).
445 *ANGPTL4* deleterious variant carrier status, excluding p.E40K, was also associated with a reduced risk
446 of CAD (meta-analysis IVW OR: 0.32 per TG, P=0.016), as was *APOC3* deleterious variant carriers
447 status (meta-analysis IVW OR: 0.70 per TG, P=0.005). The key finding was the robust association of
448 *ANGPTL3* deleterious carrier status with a reduced risk of CAD. This association was not detected with
449 the other approaches and implies that *ANGPTL3* lowering might offer atheroprotective benefits similar
450 to *ANGPTL4* or *APOC3* lowering.

Meta-analysis of Coronary Artery Disease vs. Deleterious Variants in DNA Sequencing Studies



451

452

453

454

455

456

Figure 6. Meta-analysis of deleterious variants in ANGPTL3, ANGPTL4, and APOC3, and the risk of CAD.

Forest plots and tables indicating the effect on CAD per mmol/L TG, and per allele. The deleterious variant effect estimates for each substudy were retrieved from (3, 23, 46, 52, 53). The case definition used in the Copenhagen City Heart Study was not exclusively restricted to CAD. 21% of the ischemic vascular disease cases were diagnosed with atherosclerotic cerebrovascular disease, rather than CAD (with CAD encompassing 79 % of the cases) (53). 'Eur.' denotes European ancestry.

457 **DISCUSSION**

458 We find that targeted inactivation and associated lowering of plasma APOC3 levels is predicted to
459 decrease plasma TG and LDL and raise HDL levels. Targeted lowering of plasma ANGPTL3 is expected
460 to reduce plasma TG, LDL, and HDL levels, while lowering of plasma ANGPTL4 is predicted to
461 decrease plasma TG and increase HDL levels. Based on these findings, it is expected that genetic
462 inactivation of APOC3, ANGPTL3, and ANGPTL4 levels is associated with protection against CAD.
463 Through MR and a meta-analysis of rare variant genetic association studies, we confirmed that targeted
464 inactivation and lowering of ANGPTL3, ANGPTL4, and APOC3 is associated with a lowered risk of
465 CAD. In addition, lifetime genetic lowering of ANGPTL4 was observed to reduce the risk of T2D,
466 indicating that ANGPTL4 inhibition might provide additional benefits to patients with T2D and
467 dyslipidemia.

468 The inactivation of ANGPTL4 in mice and monkeys was shown to lead to mesenteric lymphadenopathy
469 and other severe complications. Naturally, these observations raised serious concerns about the safety
470 of pharmacological targeting of ANGPTL4. Here, we did not find an association between genetic
471 ANGPTL4 inactivation and several disease codes related to lymphatic disorders. While these data do
472 not entirely exclude any harmful effects of ANGPTL4 inactivation, they do mitigate safety concerns
473 about the impact of whole-body inactivation of ANGPTL4 in humans. Recently, it was shown that
474 silencing of ANGPTL4 in the liver and adipose tissue using ASO markedly reduces plasma TG levels
475 in mice yet does not lead to mesenteric lymphadenopathy or other complications (16). These data
476 suggest that liver- and adipose tissue-specific inactivation of ANGPTL4 may confer similar
477 cardiovascular benefits as whole-body ANGPTL4 inactivation without any particular safety risks.

478 The association of ANGPTL4 with T2D was distinct from the other proteins that inhibit LPL. In
479 preclinical studies, mice overexpressing LPL in muscle were more insulin resistant, while mice lacking
480 LPL in muscle were more insulin sensitive. In contrast, mice overexpressing LPL in adipocytes were
481 more insulin sensitive (54, 55). The protective effect of enhanced LPL action in adipose tissue may be
482 related to increased lipid partitioning into the adipose tissue and reduced ectopic fat. While ANGPTL3,
483 ANGPTL4, and APOC3 all act through LPL, only ANGPTL4 acts exclusively via LPL, which may
484 explain why only genetic variation in ANGPTL4 is associated with T2D risk.

485 Previous studies reported conflicting findings regarding the association between ANGPTL3 and CAD.
486 Dewey et al. (3), and Stitzel et al. (46) found that rare deleterious *ANGPTL3* variants were associated
487 with decreased odds of ASCVD, whereas MR studies of common ANGPTL3-lowering variants reported
488 negative findings (45). By meta-analysis of deleterious variant genetic association studies, we found
489 clear, statistically robust evidence that lifetime genetic inactivation of ANGPTL3 confers protection
490 against CAD. These findings align with recent case reports indicating that ANGPTL3 lowering with
491 Evinacumab protects against atherosclerosis progression in HoFH patients (11, 12). A recent and similar
492 UK Biobank study examining the impact of protein-truncating *ANGPTL3* variants on CAD found no
493 association (56). Compared to their analysis, key differences were a broader case definition, a stricter

494 definition of controls, the inclusion of deleterious missense variants, and the meta-analysis, which
495 incorporated evidence from previous studies. These methodological differences strengthened statistical
496 power in our study, making a false negative finding less probable.

497 The discrepancy between the deleterious and common ANGPTL3 variants in terms of their association
498 with CAD could be due to a range of different factors. One possible explanation is the pleiotropic effects
499 of ANGPTL3. Besides inhibiting LPL, ANGPTL3 inhibits endothelial lipase (EL) (57). In a recent
500 paper, we showed that the LPL-independent effects of ANGPTL3 inactivation on plasma metabolic
501 parameters showed a striking inverse resemblance with EL inactivation, suggesting that ANGPTL3
502 modulates plasma lipid levels by inhibiting LPL and EL (41). Here, using MR, we compared the effects
503 of genetically instrumented EL and LPL activity on CAD. Whereas increased LPL activity reduced the
504 odds of CAD, increased EL activity increased the odds of CAD. The observed link between EL and
505 CAD is consistent with previous human genetic studies showing the possible harmful effects of a
506 genetically predicted increase in EL activity (58, 59). This suggests that ANGPTL3's interaction with
507 EL might counteract its cardiovascular benefits achieved through LPL inhibition under certain
508 physiological conditions. While our research demonstrated metabolic concordance between ANGPTL3
509 common variants and deleterious variants, it remains possible that more profound ANGPTL3
510 inactivation by deleterious variants could tip the balance in favor of LPL inhibition over EL. This shift
511 could potentially enhance the anti-atherosclerotic benefits of ANGPTL3 lowering.

512 Interestingly, the association of ANGPTL3 inactivation with CAD was only present for rare deleterious
513 variants when the carrier status was determined by DNA sequencing. This exposes the limitations of
514 drug-target MR studies using DNA micro-array-based GWAS. When rare variants are incorrectly
515 imputed, this typically introduces a one-sided loss of information that biases toward the null hypothesis,
516 leading to falsely negative findings (51). Even though the imputation quality score (e.g., 'INFO') reports
517 an imputation quality metric, this metric does not really measure the true imputation accuracy (60). The
518 imputation accuracy can only truly be determined if variant carrier status is called by genotyping (e.g.,
519 via DNA sequencing). However, studying rare variants in genetic association studies is not without
520 drawbacks. An important limitation of rare variants is statistical imprecision simply due to their rarity
521 (61). Rare variants also often emerged relatively recently and consequently are more susceptible to
522 confounding by enrichment in specific geographical regions, families, or socioeconomic strata (62).
523 Even if appropriate model adjustments are applied, subtle differences in population structure could cause
524 a small number of extra alleles to be present in the control (or case) group. This can lead to biased
525 estimates when the rare alternative allele is present in ten, or hundred individuals in total, which is often
526 the case for rare variant studies even when the total sample size is above hundreds of thousands. Overall,
527 our findings underscore the importance of combining evidence from rare deleterious and benign
528 common variants in genetic association studies of complex disease phenotypes.

529 The complexity of the *APOA1-APOA5-APOC3* locus and the potential confounding due to LD poses
530 significant challenges in separating the genetic association signals. The use of *APOC3* c.55+1G>A as a

531 genetic instrument was justified because of its independence from common variants within this region,
532 making it ideal for studying APOC3 inactivation specifically. On the other hand, the analyses of APOC3
533 inactivation that did not include the c.55+1G>A variant should be interpreted with caution. Compared
534 to clinical trials, MR analysis can exaggerate the magnitude of the effect of inactivating a gene/protein
535 (63). Cis-pQTL MR utilizing protein-coding variants warrants extra carefulness due to the possibility of
536 epitope-binding artifacts, which may complicate the precise interpretation of effect sizes. The p.E40K
537 coding variant was the only variant qualifying as a *cis*-pQTL in the *ANGPTL4* region in the Step 1-2
538 analyses. While our validation analyses suggested this specific association was not attributable to
539 epitope-binding artifacts, we still advise caution when extrapolating effect sizes from the analyses.
540 Additionally, MR and other genetic association studies estimate lifelong exposure to changed gene
541 function, while drug trials typically last 2–5 years in late adulthood. If the treatment effect
542 multiplicatively interacts with time, MR may exaggerate it. This constraint should be considered when
543 translating MR findings to predict the results of clinical trials. For *ANGPTL4*, Dewey et al. (52), found
544 that the TG levels of p.E40K homozygotes were reduced by 0.58 mmol/L (0.92 mmol/L for p.E40K
545 homozygotes vs. 1.49 mmol/L in non-carriers; relative change -39%) in a normotriglyceridemic
546 population. When translating these findings (TG reduction of 0.58 mmol/L) onto the effect size on CAD
547 found in this study, one would expect that lifetime *ANGPTL4* inactivation—in a population of
548 normotriglyceridemic individuals—results in a risk reduction corresponding to a CAD odds ratio of 0.61
549 (95% CI: 0.52–0.72).

550 In conclusion, our genetic analysis predicts that in a broader dyslipidemic patient population, therapies
551 aimed at decreasing plasma *ANGPTL3*, *ANGPTL4*, or *APOC3* levels will be effective in preventing
552 CAD without raising specific safety concerns. In addition, therapies aimed at reducing plasma levels of
553 *ANGPTL4* may provide additional benefits to patients with dyslipidemia and T2D.

554 **ETHICAL REVIEW**

555 This study analyzed scientific data that is available to the public, as detailed in **Table 1** and
556 **Supplemental Table 1**, where references to the specific datasets can be found. Analyses using
557 individual-level access to the UK Biobank Resource were conducted under Application Number
558 #148828. The Erasmus Rucphen Family study was approved by the medical ethics board of the Erasmus
559 MC Rotterdam, the Netherlands (64). All studies complied with the ethical standards outlined in the
560 Helsinki Declaration.

561 **ACKNOWLEDGEMENTS**

562 We would like to thank Prof. Cornelia van Duijn and Prof. Ko Willems van Dijk for providing access
563 to samples from the Erasmus Rucphen Family study. We would like to thank the participants and
564 researchers of the CARDIoGRAMplusC4D, CKDGen, deCODE, DIAGRAM, EPIC-CVD, FinnGen,
565 GIGASTROKE, GLGC, and UK biobank studies, as well as the other non-consortium studies.

566 **FUNDING**

567 This research received no specific grants from public or non-profit funding agencies.

568 **CONFLICT OF INTEREST**

569 F.L. is a part-time employee of Lipigon Pharmaceuticals AB. S.K.N. is the chief executive officer of
570 Lipigon. S.K. is a paid consultant for Lipigon.

571 **DATA AVAILABILITY STATEMENT**

572 Database identifiers and links to the public data sets are provided in **Supplemental Table 1**. Access to
573 UK Biobank data is limited to authorized researchers who comply with data use policies to safeguard
574 participant confidentiality. Interested researchers must apply to UK Biobank, adhering to an application
575 process that ensures ethical and legal compliance in data handling. UK Biobank data set identifiers used
576 for the analyses under Application Number #148828 are provided in the **Supplemental Methods**. The
577 data from the Erasmus Rucphen Family study (ERF) cannot be shared publicly due to data protection
578 laws. Access to this data is restricted to ensure participant confidentiality, aligning with legal and ethical
579 obligations. Any request for access to the data for legitimate scientific purposes can be directed to the
580 principal investigators of the ERF study, subject to a rigorous review process ensuring that all legal and
581 ethical standards are met. The analyses in this manuscript were performed using the R programming
582 language (v.4.2.1) with the packages coloc, cowplot, data.table, ggplot2, ggthemes, mungegwas,
583 phewas, twosamplemr, wesanderson, writexl, and the Python programming language (v.3.8.16) using
584 the packages numpy, pandas, and scipy. The LD matrix estimates were calculated using PLINK
585 (v1.90b6.24).

586 REFERENCES

- 587 1. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, et al.
588 Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
589 *Eur Heart J*. 2022;43(14):1401-12.
- 590 2. Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, Sasiela WJ, et al. Inhibition of Angiotensin-
591 Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. *Circulation*.
592 2019;140(6):470-86.
- 593 3. Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and
594 Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. *N Engl J Med*. 2017;377(3):211-21.
- 595 4. Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, et al. ANGPTL3 Inhibition in Homozygous
596 Familial Hypercholesterolemia. *N Engl J Med*. 2017;377(3):296-7.
- 597 5. Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for
598 Homozygous Familial Hypercholesterolemia. *N Engl J Med*. 2020;383(8):711-20.
- 599 6. Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, et al. Evinacumab in Patients
600 with Refractory Hypercholesterolemia. *N Engl J Med*. 2020;383(24):2307-19.
- 601 7. Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Huh E, Kingsbury J, Bartlett VJ, et al. Vupanorsen,
602 an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic
603 lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. *Eur Heart J*.
604 2020;41(40):3936-45.
- 605 8. Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, et al. Cardiovascular and Metabolic Effects of
606 ANGPTL3 Antisense Oligonucleotides. *N Engl J Med*. 2017;377(3):222-32.
- 607 9. Watts GF, Schwabe C, Scott R, Gladding P, Sullivan D, Baker J, et al. Abstract 15751:
608 Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiotensin-like
609 Protein 3, in Patients With Hypercholesterolemia. *Circulation*. 2020;142(Suppl_3):A15751-A.
- 610 10. Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, et al. Effect of Vupanorsen on
611 Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol:
612 TRANSLATE-TIMI 70. *Circulation*. 2022;145(18):1377-86.
- 613 11. Reeskamp LF, Nurmohamed NS, Bom MJ, Planken RN, Driessen RS, van Diemen PA, et al. Marked
614 plaque regression in homozygous familial hypercholesterolemia. *Atherosclerosis*. 2021;327:13-7.
- 615 12. Khoury E, Lauzière A, Raal FJ, Mancini J, Gaudet D. Atherosclerotic plaque regression in homozygous
616 familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-
617 independent mechanisms. *Eur Heart J Case Rep*. 2023;7(1):ytad029.
- 618 13. Desai U, Lee EC, Chung K, Gao C, Gay J, Key B, et al. Lipid-lowering effects of anti-angiotensin-like 4
619 antibody recapitulate the lipid phenotype found in angiotensin-like 4 knockout mice. *Proc Natl Acad Sci U S A*.
620 2007;104(28):11766-71.
- 621 14. Lichtenstein L, Mattijssen F, de Wit NJ, Georgiadi A, Hooiveld GJ, van der Meer R, et al. Angptl4
622 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric
623 lymph node macrophages. *Cell Metab*. 2010;12(6):580-92.
- 624 15. Oteng AB, Bhattacharya A, Brodessa S, Qi L, Tan NS, Kersten S. Feeding Angptl4^{-/-} mice trans fat
625 promotes foam cell formation in mesenteric lymph nodes without leading to ascites. *J Lipid Res*.
626 2017;58(6):1100-13.
- 627 16. Deng M, Kutrolli E, Sadewasser A, Michel S, Joibari MM, Jaschinski F, et al. ANGPTL4 silencing via
628 antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy.
629 *J Lipid Res*. 2022;63(7):100237.
- 630 17. Davies BSJ. Can targeting ANGPTL proteins improve glucose tolerance? *Diabetologia*.
631 2018;61(6):1277-81.
- 632 18. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in
633 Mendelian randomization: comparison of allele score and summarized data methods. *Stat Med*.
634 2016;35(11):1880-906.
- 635 19. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, et al. Genetic drug
636 target validation using Mendelian randomisation. *Nat Commun*. 2020;11(1):3255.
- 637 20. Timpson NJ, Walter K, Min JL, Tachmazidou I, Malerba G, Shin SY, et al. A rare variant in APOC3 is
638 associated with plasma triglyceride and VLDL levels in Europeans. *Nat Commun*. 2014;5:4871.
- 639 21. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrismisdottir EL, et al. Large-
640 scale integration of the plasma proteome with genetics and disease. *Nat Genet*. 2021;53(12):1712-21.
- 641 22. Dhindsa RS, Burren OS, Sun BB, Prins BP, Matelska D, Wheeler E, et al. Rare variant associations with
642 plasma protein levels in the UK Biobank. *Nature*. 2023;622(7982):339-47.
- 643 23. Wang Q, Dhindsa RS, Carss K, Harper AR, Nag A, Tachmazidou I, et al. Rare variant contribution to
644 human disease in 281,104 UK Biobank exomes. *Nature*. 2021;597(7877):527-32.
- 645 24. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic
646 insights from a well-phenotyped isolated population. *Nature*. 2023;613(7944):508-18.
- 647 25. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access
648 resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*.
649 2015;12(3):e1001779.
- 650 26. Slatkin M. Linkage disequilibrium--understanding the evolutionary past and mapping the medical
651 future. *Nat Rev Genet*. 2008;9(6):477-85.
- 652 27. Zuber V, Grinberg NF, Gill D, Manipur I, Slob EAW, Patel A, et al. Combining evidence from Mendelian
653 randomization and colocalization: Review and comparison of approaches. *Am J Hum Genet*. 2022;109(5):767-
654 82.

- 655 28. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for
656 colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet.*
657 2014;10(5):e1004383.
- 658 29. Abraham W. The Fitting of Straight Lines if Both Variables are Subject to Error. *The Annals of*
659 *Mathematical Statistics.* 1940;11(3):284-300.
- 660 30. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, et al. Discovery and systematic
661 characterization of risk variants and genes for coronary artery disease in over a million participants. *Nat Genet.*
662 2022;54(12):1803-15.
- 663 31. Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of genetic loci associated with
664 kidney function from analyses of a million individuals. *Nat Genet.* 2019;51(6):957-72.
- 665 32. Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, et al. Stroke genetics informs drug
666 discovery and risk prediction across ancestries. *Nature.* 2022;611(7934):115-23.
- 667 33. Ghodsian N, Abner E, Emdin CA, Gobeil É, Taba N, Haas ME, et al. Electronic health record-based
668 genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease.
669 *Cell Rep Med.* 2021;2(11):100437.
- 670 34. Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-mapping type 2
671 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat*
672 *Genet.* 2018;50(11):1505-13.
- 673 35. Nag A, Dhindsa RS, Middleton L, Jiang X, Vitsios D, Wigmore E, et al. Effects of protein-coding variants
674 on blood metabolite measurements and clinical biomarkers in the UK Biobank. *Am J Hum Genet.*
675 2023;110(3):487-98.
- 676 36. Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU OpenGWAS data
677 infrastructure. *bioRxiv.* 2020:2020.08.10.244293.
- 678 37. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over
679 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet.* 2018;50(10):1412-25.
- 680 38. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of genome-
681 wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet.*
682 2019;28(1):166-74.
- 683 39. Stanzick KJ, Li Y, Schlosser P, Gorski M, Wuttke M, Thomas LF, et al. Discovery and prioritization of
684 variants and genes for kidney function in >1.2 million individuals. *Nat Commun.* 2021;12(1):4350.
- 685 40. Liu Y, Basty N, Whitcher B, Bell JD, Sorokin EP, van Bruggen N, et al. Genetic architecture of 11 organ
686 traits derived from abdominal MRI using deep learning. *Elife.* 2021;10.
- 687 41. Landfors F, Chorell E, Kersten S. Genetic Mimicry Analysis Reveals the Specific Lipases Targeted by the
688 ANGPTL3-ANGPTL8 Complex and ANGPTL4. *J Lipid Res.* 2023;64(1):100313.
- 689 42. Wang Q, Oliver-Williams C, Raitakari OT, Viikari J, Lehtimäki T, Kahonen M, et al. Metabolic profiling of
690 angiotensin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis. *Eur Heart J.*
691 2021;42(12):1160-9.
- 692 43. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl Variant Effect
693 Predictor. *Genome Biol.* 2016;17(1):122.
- 694 44. Yin W, Romeo S, Chang S, Grishin NV, Hobbs HH, Cohen JC. Genetic variation in ANGPTL4 provides
695 insights into protein processing and function. *J Biol Chem.* 2009;284(19):13213-22.
- 696 45. Richardson TG, Leyden GM, Wang Q, Bell JA, Elsworth B, Davey Smith G, et al. Characterising
697 metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation. *PLoS Biol.*
698 2022;20(2):e3001547.
- 699 46. Stitzel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 Deficiency and
700 Protection Against Coronary Artery Disease. *J Am Coll Cardiol.* 2017;69(16):2054-63.
- 701 47. Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et al. Exome sequencing,
702 ANGPTL3 mutations, and familial combined hypolipidemia. *N Engl J Med.* 2010;363(23):2220-7.
- 703 48. Kovrov O, Kristensen KK, Larsson E, Ploug M, Olivecrona G. On the mechanism of angiotensin-like
704 protein 8 for control of lipoprotein lipase activity. *J Lipid Res.* 2019;60(4):783-93.
- 705 49. Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, et al. A novel endothelial-derived
706 lipase that modulates HDL metabolism. *Nat Genet.* 1999;21(4):424-8.
- 707 50. Cherukuri PF, Soe MM, Condon DE, Bartaria S, Meis K, Gu S, et al. Establishing analytical validity of
708 BeadChip array genotype data by comparison to whole-genome sequence and standard benchmark datasets.
709 *BMC Med Genomics.* 2022;15(1):56.
- 710 51. Stahl K, Gola D, König IR. Assessment of Imputation Quality: Comparison of Phasing and Imputation
711 Algorithms in Real Data. *Front Genet.* 2021;12:724037.
- 712 52. Dewey FE, Gusarova V, O'Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating Variants in
713 ANGPTL4 and Risk of Coronary Artery Disease. *N Engl J Med.* 2016;374(12):1123-33.
- 714 53. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in
715 APOC3 and risk of ischemic vascular disease. *N Engl J Med.* 2014;371(1):32-41.
- 716 54. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, et al. Tissue-specific overexpression of
717 lipoprotein lipase causes tissue-specific insulin resistance. *Proc Natl Acad Sci U S A.* 2001;98(13):7522-7.
- 718 55. Walton RG, Zhu B, Unal R, Spencer M, Sunkara M, Morris AJ, et al. Increasing adipocyte lipoprotein
719 lipase improves glucose metabolism in high fat diet-induced obesity. *J Biol Chem.* 2015;290(18):11547-56.
- 720 56. Gobeil É, Bourgault J, Mitchell PL, Houessou U, Gagnon E, Girard A, et al. Genetic inhibition of
721 angiotensin-like protein-3, lipids, and cardiometabolic risk. *Eur Heart J.* 2024;45(9):707-21.
- 722 57. Gusarova V, Alexa CA, Wang Y, Rafique A, Kim JH, Buckler D, et al. ANGPTL3 blockade with a human
723 monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. *J Lipid Res.* 2015;56(7):1308-
724 17.
- 725 58. Thomas DG, Wei Y, Tall AR. Lipid and metabolic syndrome traits in coronary artery disease: a
726 Mendelian randomization study. *J Lipid Res.* 2021;62:100044.

- 727 59. Singaraja RR, Sivapalaratnam S, Hovingh K, Dubé MP, Castro-Perez J, Collins HL, et al. The impact of
728 partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and
729 functionality in humans. *Circ Cardiovasc Genet*. 2013;6(1):54-62.
- 730 60. Zheng HF, Rong JJ, Liu M, Han F, Zhang XW, Richards JB, et al. Performance of genotype imputation
731 for low frequency and rare variants from the 1000 genomes. *PLoS One*. 2015;10(1):e0116487.
- 732 61. Zuk O, Schaffner SF, Samocha K, Do R, Hechter E, Kathiresan S, et al. Searching for missing
733 heritability: designing rare variant association studies. *Proc Natl Acad Sci U S A*. 2014;111(4):E455-64.
- 734 62. Locke AE, Steinberg KM, Chiang CWK, Service SK, Havulinna AS, Stell L, et al. Exome sequencing of
735 Finnish isolates enhances rare-variant association power. *Nature*. 2019;572(7769):323-8.
- 736 63. Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian randomisation to assess
737 potential benefit of clinical intervention. *BMJ*. 2012;345:e7325.
- 738 64. Henneman P, Aulchenko YS, Frants RR, van Dijk KW, Oostra BA, van Duijn CM. Prevalence and
739 heritability of the metabolic syndrome and its individual components in a Dutch isolate: the Erasmus Rucphen
740 Family study. *J Med Genet*. 2008;45(9):572-7.
- 741 65. Jonker JT, Smit JW, Hammer S, Snel M, van der Meer RW, Lamb HJ, et al. Dietary modulation of
742 plasma angiopoietin-like protein 4 concentrations in healthy volunteers and in patients with type 2 diabetes. *Am*
743 *J Clin Nutr*. 2013;97(2):255-60.

744

745 **APPENDICES**

746

747 **Supplemental Note**

748 This document contains the **Supplemental Methods**. The supplemental note *.pdf* also contains

749 **Supplemental Figures 1–6**.

750

751 **Supplemental Figures**

752 *The Supplemental Figures 1–6 are contained within the supplemental note .pdf file.*

753 **Supplemental Figure 1. Scatter plots showing the results of the drug-target MR analyses.** Each

754 subplot represents the results of the analyses displayed in **Figures 2–4** of the main manuscript that

755 used more than one genetic instrument.

756 **Supplemental Figure 2. Regional genetic association plots showing the results of the**

757 **colocalization analyses.** Each subplot represents the results of the analyses displayed in **Figure 2–4** of

758 the main manuscript.

759 **Supplemental Figure 3. Results of cis-pQTL MR analyses of the estimated glomerular filtration**

760 **rate by (eGFR) by Cystatin C and plasma Creatinine.** The findings are displayed in bar graphs,

761 illustrating the level of the effect per s.d. decrease in protein abundance. The red lines represent the 95%

762 CI.

763 **Supplemental Figure 4. Results of phenome-wide MR analysis on FinnGen outcomes using**

764 *ANGPTL3 rs34483103-1:62604866:AGTTAATGTG>A [3 prime UTR, c.*52_*60del]* and *APOC3*

765 *rs138326449-11:116830638:G>A [donor loss, c.55+1G>A]* variants. **A:** Volcano plot displaying the

766 results of *ANGPTL3* cis-pQTL phenome-wide MR. **B:** *APOC3* cis-pQTL phenome-wide MR volcano

767 plot. The y-axis solid straight lines indicate the phenome-wide significance threshold. ‘OR’ indicates

768 the odds ratio with 95% confidence intervals with Bonferroni correction for the 694 FinnGen

769 outcomes.

770 **Supplemental Figure 5. Cis-pQTL MR of the clinical laboratory outcomes, showing the results on**

771 **a 1-s.d. scale.** The red bars indicate the 95 % CI. The black dots indicate the effect point estimate. ‘*’

772 indicate $P < 0.05$. ‘***’ indicates $P < 0.05$ with a shared causal variant (H_4). A list explaining the

773 abbreviations is provided in the supplemental material (**Supplemental Table 1**).

774 **Supplemental Figure 6. Wildtype human ANGPTL4 protein and the ANGPTL4 E40K variant**
775 **protein are detected to a similar extent by the antibody used in the human ANGPTL4 ELISA.**

776 Western blot of the precipitated medium of HEK293 cells transfected with expression vectors for

777 different mutant forms of human ANGPTL4 fused to a V5-tag (65). CC/AA is an oligomerization

778 defective ANGPTL4 variant. SDS-PAGE was performed using a loading buffer without DTT or other

779 disulfide-reducing agent. Equal amounts of medium were loaded. Membranes were blotted with an

780 antibody from R&D Systems that is used for the human ANGPTL4 Elisa (AF3485, 1:2500). Secondary
781 antibody was goat anti-rabbit IgG conjugated to HRP (1:5000).

782

783 **Supplemental Tables**

784 *The Supplemental Tables 1-10 are located within the supplemental_tables_1_10.xlsx file. The .xlsx file*
785 *is available via a public repository and can be accessed via the following link:*

786 <https://doi.org/10.5281/zenodo.10880711>

787 **Supplemental Table 1. Description of GWAS data sets**

788 List of the GWAS data sets used. 'database.ID' denotes the EBI GWAS catalog identifiers if starting
789 by "GCST", or the UK biobank showcase identifier if starting by a number.

790 **Supplemental Table 2. MR results with 1000Genomes LD matrix**

791 Results of the MR analyses that are presented in the paper. 'rsids.dbsnp.ver144' denote the rsids that
792 were used in each MR model.

793 **Supplemental Table 3. MR sensitivity analysis w. UKB 337K LD matrix vs. 1000Genomes.**

794 LD matrix sensitivity analysis using the 1000Genomes and UKB 337K LD
795 matrices.'heterogeneity.statistic' indicates the heterogeneity P-value, which is described in detail in the
796 supplemental note.

797 **Supplemental Table 4. MR sample overlap risk of bias analysis**

798 Result of the risk of bias from sample overlap analysis reporting the F-statistics, bias
799 ('Beta.bias.low.scenario', 'Beta.bias.medium.scenario', and 'Beta.bias.high.scenario') and type 1 error
800 inflation (Type1error.lowbias.scenario, Type1error.mediumbias.scenario,
801 Type1error.highbias.scenario) for each scenario and model.

802 **Supplemental Table 5. ICD codes used for UKB lymphadenopathy-related phecodes**

803 Phecode and ICD-codes as described in the Methods section.

804 **Supplemental Table 6. ANGPTL4 p.40K pQTL MR PheWAS results**

805 Detailed results of the MR analyses presented in **Figure 4D**.

806 **Supplemental Table 7. ANGPTL4 p.Cys80fs pQTL MR PheWAS results**

807 Detailed results of the MR analyses presented in **Figure 4D**.

808 **Supplemental Table 8. ANGPTL3 rs34483103-1:62604866:AGTTAATGTG>A [3 prime UTR, 809 c.*52_*60del] pQTL MR PheWAS results**

810 Detailed results of the MR analyses presented in **Supplemental Figure 4A**.

811 **Supplemental Table 9. APOC3 rs138326449-11:116830638:G>A [donor loss, c.55+1G>A] pQTL 812 MR PheWAS results**

813 Detailed results of the MR analyses presented in **Supplemental Figure 4B**.

814 **Supplemental Table 10. List of variants used in the UK Biobank genetic association analyses**

815 'rsID' indicates the NCBI Reference SNP cluster ID. 'REVEL' denotes the Rare Exome Variant
816 Ensemble Learner pathogenicity prediction score for missense variants.